sanjeri / iStockphoto.com
Italy-based research organisation IRBM has signed a new agreement with Merck & Co in the peptides therapeutics area, extending the parties’ long-standing collaboration.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
IRBM, Merck & Co, MSD, peptide therapeutics, collaboration, therapeutics, drug development